{"id":"paper-or-2026-089591","type":"book","url":"https://diginpl.com/books/paper-or-2026-089591","language":"en","name":"Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis","name_en":"Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis","name_ne":null,"description":"Oncology Research · Karolina Winsko-Szczęsnowicz, Aleksandra Konieczna, Katarzyna Świderska et al. · 2026","headline":"Oncology Research · Karolina Winsko-Szczęsnowicz, Aleksandra Konieczna, Katarzyna Świderska et al. · 2026","also_known_as":[],"summary":"","summary_more":[],"facts":[{"key":"authors","label":"Author","values":[{"text":"Karolina Winsko-Szczęsnowicz"},{"text":"Aleksandra Konieczna"},{"text":"Katarzyna Świderska"},{"text":"Miloš Holánek"},{"text":"Roman Dubiański"},{"text":"Lenka Rušinová"},{"text":"Małgorzata Pieniążek"},{"text":"Anika Pękala"}],"source":{"label":"Crossref","url":"https://doi.org/10.32604/or.2026.089591"}},{"key":"published","label":"Published","values":[{"text":"2026","date":"2026"}],"source":{"label":"Crossref","url":"https://doi.org/10.32604/or.2026.089591"}},{"key":"publisher","label":"Publisher","values":[{"text":"Tech Science Press"}],"source":{"label":"Crossref","url":"https://doi.org/10.32604/or.2026.089591"}},{"key":"journal","label":"Journal","values":[{"text":"Oncology Research"}],"source":{"label":"Crossref","url":"https://doi.org/10.32604/or.2026.089591"}},{"key":"doi","label":"DOI","values":[{"text":"10.32604/or.2026.089591","url":"https://doi.org/10.32604/or.2026.089591"}],"source":{"label":"Crossref","url":"https://doi.org/10.32604/or.2026.089591"}}],"office":null,"sections":[],"cited":[],"cited_from":null,"videos":[],"last_reviewed":null,"organizations":[],"same_as":["https://doi.org/10.32604/or.2026.089591"],"faq":[{"q":"Who wrote Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis?","a":"Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis was written by Karolina Winsko-Szczęsnowicz, Aleksandra Konieczna, Katarzyna Świderska, Miloš Holánek."},{"q":"When was Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis first published?","a":"Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis was first published in 2026."}],"related":[],"places_in":[],"nearby":[],"image":null,"sources":[{"label":"Publisher record (DOI, via Crossref)","url":"https://doi.org/10.32604/or.2026.089591","license":null}],"license":null,"attribution":"Open-access publication. Read it free at the publisher: https://doi.org/10.32604/or.2026.089591.","cite":"\"Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis\". DigiNepal. Last updated 10 November 2026. https://diginpl.com/books/paper-or-2026-089591. Retrieved 14 November 2026.","date_modified":"2026-11-10T06:52:07Z","facts_checked":"2026-11-10","alternates":{"html":"https://diginpl.com/books/paper-or-2026-089591","en":"https://diginpl.com/books/paper-or-2026-089591","ne":null}}